onc Videos

Videos

Videos

Second-Line Cilta-cel Improves Outcomes for Patients With Functional High-Risk Multiple Myeloma vs Standard of Care Therapy

06/07/2024

Featuring Luciano Costa, MD

Cilta-cel improved outcomes for patients with lenalidomide-refractory functional high-risk multiple myeloma vs standard of care, according to data presented by Luciano Costa, MD, at the 2024 ASCO Annual Meeting.

Cilta-cel improved outcomes for...

06/07/2024

Oncology

Conference Coverage

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

06/07/2024

Featuring Maria-Victoria Mateos, MD, PhD

Featuring Maria-Victoria Mateos, MD, ...

Maria-Victoria Mateos, MD, PhD, presents results from the phase 3 DREAMM-7 trial, which demonstrated the efficacy of belantamab mafodotin plus bortezomib and dexamethasone as a potential new standard of care for patients with R/R MM.

Maria-Victoria Mateos, MD, PhD,...

06/07/2024

Oncology

Rebecca Shatsky, MD, University of California, San Diego

Videos

Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer

06/07/2024

Rebecca Shatsky, MD

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Rebecca Shatsky, MD, shares...

06/07/2024

Oncology

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Prophylactic Tocilizumab Prior to Outpatient Step-Up Administration of Teclistamab Lowers CRS Among Patients With R/R MM

06/04/2024

Featuring Robert Rifkin, MD

Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.

Robert Rifkin, MD, discusses...

06/04/2024

Oncology

David Andorsky, MD, Rocky Mountain Cancer Centers

Videos

Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients

06/04/2024

Featuring David Andorsky, MD

David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.

David Andorsky, MD, shares...

06/04/2024

Oncology

Videos

Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting

06/04/2024

Featuring John Burke, MD

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

John Burke, MD, discusses some...

06/04/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/03/2024

Xichun Hu, MD, PhD

Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...

Xichun Hu, MD, PhD, Fudan...

06/03/2024

Oncology

Conference Coverage

Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

06/03/2024

Don Dizon, MD

Don Dizon, MD, discusses the results from the phase 2 BrUOG 354 trial evaluating nivolumab with/without ipilimumab among patients with ovarian and extra-renal clear cell carcinoma.

Don Dizon, MD, discusses the...

06/03/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

06/03/2024

Jane Meisel, MD

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

Jane Meisel, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Subcutaneous Epcoritamab Demonstrated Efficacy Among Patients With R/R DLBCL and FL Treated in the Outpatient Setting

06/03/2024

Featuring David Andorsky, MD

David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.

David Andorsky, MD, discussed...

06/03/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology